Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Single-dose psilocybin superior to placebo for MDD in community settingThe Brown University Psychopharmacology Update · 2026-12-01Pilot study supports broader research on psilocybin for anorexia nervosaThe Brown University Psychopharmacology Update · 2026-12-01Single dose of psilocybin shows extended benefit in depression trialThe Brown University Psychopharmacology Update · 2026-12-01Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelPsychedelics · 2026-12-01Taxonomic diversity and psilocybin detection in “superfamily” Strophariacea from China, with descriptions of two new speciesIMA Fungus · 2026-11-18Novel quantification method for psilocin in brain tissues using liquid chromatography-tandem mass spectrometry.Analytical methods: advancing methods and applications · 2026-11-18Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-11-18Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted PsychotherapyClinicalTrials.gov · 2026-11-18An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-11-17Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-11-17A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for DepressionClinicalTrials.gov · 2026-11-17Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-11-16Prior trauma shapes the effects of psilocybin on stress sensitization in mice.Neuroscience letters · 2026-11-15Psilocybin enhances conditioned place preference learning in planarians.Behavioural pharmacology · 2026-11-13Connectedness as a candidate pathway linking psilocybin retreat experiences to sustained wellbeing: a prospective naturalistic studyFrontiers in psychiatry · 2026-11-12The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-11-12Psilocybin With Intracranial Neural SensingClinicalTrials.gov · 2026-11-12NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-11-12A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-11-12Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disordersInternational Health Sciences Review · 2026-11-10Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patientsPhilosophical Transactions of the Royal Society B: Biological Sciences · 2026-11-10Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who StutterClinicalTrials.gov · 2026-11-10Psilocybin for anorexia nervosa: efficacy, safety, and durability of clinical effects: a systematic review of clinical trialsDebates em Psiquiatria · 2026-11-09Psilocybin Recovery Intervention for Stopping Methamphetamine UseClinicalTrials.gov · 2026-11-09Pharmacist Guide to Psilocybin and Psychedelic-Assisted Psychotherapy.American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists · 2026-11-06Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive DisorderClinicalTrials.gov · 2026-11-06Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)ClinicalTrials.gov · 2026-11-06A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?ClinicalTrials.gov · 2026-11-06Psilocybin for Amblyopia - Targeting Critical Periods in Humans (PATCH)ClinicalTrials.gov · 2026-11-05Which Psychedelic Therapy Should Rural Health Systems Pursue First: Psilocybin or Ibogaine?The Permanente Journal · 2026-11-05Psilocybin modulates nucleus accumbens activity via astrocytic transcriptional regulation.Experimental & molecular medicine · 2026-11-05A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)ClinicalTrials.gov · 2026-11-05Pilot Study of Psilocybin-assisted Treatment for Cannabis Use DisorderClinicalTrials.gov · 2026-11-05Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-11-05Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderClinicalTrials.gov · 2026-11-05A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back PainClinicalTrials.gov · 2026-11-04TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-11-03TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-11-03Psilocybin FCR Early-Stage Breast CancerClinicalTrials.gov · 2026-11-02PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-11-02A multi-institutional investigation of psilocybin's effects on mouse behavior.Nature neuroscience · 2026-11-02Furthering the Understanding of Psilocybin Use and Molecules Relevant to Depression and Schizophrenia.The American journal of psychiatry · 2026-11-01Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH.Clinical drug investigation · 2026-11-01Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.CNS drugs · 2026-11-01Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary AnalysisJournal of Pain and Symptom Management · 2026-11-01α-Adrenergic receptor modulates 5-HT-mediated behavioral effects of MDMA and psilocybin in mice.Molecular psychiatry · 2026-11-01Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.The International journal of eating disorders · 2026-11-01Safety and efficacy of psilocybin-assisted therapy for alcohol use disorder: Open-label extension of a phase II randomized controlled trialDrug and Alcohol Dependence · 2026-11-01Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant DepressionValue in Health Regional Issues · 2026-11-01Prevalence and Correlates of Past-Year Psilocybin Use in the United StatesAmerican Journal of Psychiatry · 2026-11-01Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-11-01The Fireside Database: Large-scale evidence from 25,419 psychedelic support interactions.Science advances · 2026-10-30Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-10-30Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-10-30Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.Journal of affective disorders · 2026-10-30A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-10-29A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-10-29An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality DisorderClinicalTrials.gov · 2026-10-29High-Quality Genome Assembly and Transcriptomic Analysis Reveal Potential Pathways for Psilocybin Biosynthesis in Gymnopilus dilepisJournal of Fungi · 2026-10-28Psychedelic assisted psychotherapy (2020-2025): a scoping review of clinical evidence, mechanisms, safety, and ethicsFrontiers in Psychology · 2026-10-27Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-10-27Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among VeteransClinicalTrials.gov · 2026-10-26Substantial Treatment-Seeking Interest, Narrow Eligibility: Diagnostic Heterogeneity and External Validity in the PRIDE Psilocybin Trial-Relevance to Precision PsychiatryBehavioral Sciences · 2026-10-26Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.JAMA · 2026-10-26Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis.Psychopharmacology · 2026-10-26Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-10-26Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-10-26Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-10-26Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patientsFrontiers in psychiatry · 2026-10-24Sustained antidepressant-like effects of psychedelics through 5-HT2AR-β-arrestin signaling.Nature neuroscience · 2026-10-23Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-10-23A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-10-23Mikrodosiertes Psilocybin im palliativmedizinischen KontextSchmerz Nachrichten · 2026-10-21Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease: A Nonrandomized Clinical Trial.JAMA psychiatry · 2026-10-21A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-10-21Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-10-21Clinical Evidence on Psilocybin and Its Representation in Media ReportingJAMA Network Open · 2026-10-20Direct Quantitation of Psilocybin and Psilocin by H and P qNMR in Wild from Greece.ACS omega · 2026-10-20A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-10-20Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-10-20Microdosing Psychedelics to Improve MoodClinicalTrials.gov · 2026-10-20Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain DurabilityTherapeutics · 2026-10-19Psychoplastogens to Reduce Persistent Cognitive Symptoms for Traumatic Brain Injury as a Chronic Condition.Journal of neurotrauma · 2026-10-19Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-10-19A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-10-19Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice.Psychopharmacology · 2026-10-17The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of PsilocybinClinicalTrials.gov · 2026-10-16Coding and Classification Errors in Study of Psilocybin ServicesJAMA Network Open · 2026-10-16Stroboscopic light stimulation as a controllable probe of the psilocybin state: a mechanistic framework and a falsifiable predictionFrontiers in pharmacology · 2026-10-16Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-10-16Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.ClinicalTrials.gov · 2026-10-16Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot StudyClinicalTrials.gov · 2026-10-16Aspirational Autonomy and Psychedelic-Assisted Therapy in Advanced Cancer: Ethical Lessons from Clinical Cases.The oncologist · 2026-10-155-HT2A receptors in layer 5 pyramidal neurons mediate the neuroplastic but not the hallucinogenic effects of psilocybin.Nature neuroscience · 2026-10-15Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled TrialClinicalTrials.gov · 2026-10-15Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways.CNS & neurological disorders drug targets · 2026-10-14A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced CancerClinicalTrials.gov · 2026-10-14Acute anxiogenic effects of psilocybin and the related tryptamine, norbaeocystin, in male and female rats.Psychopharmacology · 2026-10-13Cannabis and Psilocybin Co-use: Associations with Stress and Well-beingInternational Journal of Mental Health and Addiction · 2026-10-13Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant responseNeuropsychopharmacology · 2026-10-12Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb PainClinicalTrials.gov · 2026-10-09Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-10-09Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysisJournal of Psychopharmacology · 2026-10-08Pilot Study on the Effects of Psilocybin on Belief Updating and Insight FormationClinicalTrials.gov · 2026-10-08Music for psilocybin therapy and the temporal arc of psychedelic experienceScientific Reports · 2026-10-08Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male miceFrontiers in pharmacology · 2026-10-07What Is Psilocybin?JAMA · 2026-10-06Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-10-06PsilocybinJAMA · 2026-10-06Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentClinicalTrials.gov · 2026-10-05Placebo, Psilocybin und der vermaledeite p-WertNervenheilkunde · 2026-10-01Open-label, Single-arm fMRI Study Evaluating the Effects of Psilocybin on Craving in Nicotine Dependence.ClinicalTrials.gov · 2026-10-01Embeddedness under psilocybin.Nature neuroscience · 2026-10-01The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policyPsychedelics · 2026-10-01MedCheck: Drugmakers Advance Psilocybin, Oral Pregnanolone for MDD, Plus FDA Approves Pediatric Tourette's Drug, and MorePsychiatric News · 2026-10-01Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's diseaseNeuroscience Research · 2026-10-01Oregon’s State-Regulated Psilocybin Services: Early Real-World Safety SignalsPsyArXiv · 2026-10-01Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-10-01Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.Journal of psychiatric research · 2026-10-01The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSDClinicalTrials.gov · 2026-10-01Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in ratsPharmacology Biochemistry and Behavior · 2026-10-01Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.Community mental health journal · 2026-10-01Large-Scale and Local Functional Connectivity Changes following Psilocybin Administration in Methamphetamine Use Disorder.AJNR. American journal of neuroradiology · 2026-10-01Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats.Neuroscience bulletin · 2026-10-01Worsening of Depression and Anxiety With Psilocybin: A Case Report in Cyclothymia.The Journal of clinical psychiatry · 2026-09-30Psilocybin in psychiatry: Current clinical evidence, mechanisms of action and translational perspectives. A literature review based on PubMed-indexed studiesPharmacotherapy in Psychiatry and Neurology · 2026-09-29Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMTJAMA Network Open · 2026-09-29Targeting the serotonin 1B receptor for the treatment of depression and anxiety.Expert opinion on therapeutic targets · 2026-09-28The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-09-28Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-09-24Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-09-24Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-09-23ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-09-22EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEWInternational Journal of Innovative Technologies in Social Science · 2026-09-21A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy AdultsPharmaceuticals · 2026-09-21Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.British journal of clinical pharmacology · 2026-09-21An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.The Journal of clinical psychiatry · 2026-09-21A Case of Acute Mania and Rhabdomyolysis Associated With Long-Term, Daily Psilocybin Use.Journal of clinical psychopharmacology · 2026-09-21Psilocybin in the Treatment of Methamphetamine Use DisorderClinicalTrials.gov · 2026-09-21Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)ClinicalTrials.gov · 2026-09-21Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2026-09-19Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.Mini reviews in medicinal chemistry · 2026-09-18High ventilation breathwork as a non-pharmacological model for inducing psychedelic-like states: expert evaluations of therapeutic potential and risk.Npj mental health research · 2026-09-17Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal-hippocampal circuitry.Molecular psychiatry · 2026-09-17Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disordersnpj Mental Health Research · 2026-09-16Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCDFrontiers in psychiatry · 2026-09-16Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation serviceFrontiers in Public Health · 2026-09-16A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-09-165-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice.Chinese medical journal · 2026-09-15PRoMiSS: Psilocybin and the Role of Music in Set and SettingClinicalTrials.gov · 2026-09-15Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual AnhedoniaClinicalTrials.gov · 2026-09-15Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled TrialClinicalTrials.gov · 2026-09-15Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology.Psychopharmacology · 2026-09-15MDMA and Psilocybin Regulate Oligodendrocyte-Lineage Cell Numbers and Anxiety-Like Behaviors in a Rat Model of Fear.Biological psychiatry · 2026-09-15Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-09-14Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.Cureus · 2026-09-13[The use of psychedelics in psychiatry].Orvosi hetilap · 2026-09-13Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network OrganizationAnesthesia Research · 2026-09-11A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility TrialClinicalTrials.gov · 2026-09-09A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-09-09Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner ViolenceClinicalTrials.gov · 2026-09-08Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCDFrontiers in Psychiatry · 2026-09-08Psilocybin as a treatment for repetitive mild head injury: evidence from neuroradiology and molecular biologyCommunications Biology · 2026-09-08Psilocybin as an emerging anxiolytic: mechanisms, evidence, and open questions.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-09-06Daily briefing: Psilocybin blocks side-effect of chemotherapy in mice.Nature · 2026-09-04Psilocybin-induced changes in electroencephalography link acute and long-term effects.Journal of psychopharmacology (Oxford, England) · 2026-09-04Effects of Psilocybin in Obsessive Compulsive DisorderClinicalTrials.gov · 2026-09-04Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's DiseaseClinicalTrials.gov · 2026-09-04Psilocybin and Affective Function in Chronic Lower Back Pain DepressionClinicalTrials.gov · 2026-09-04Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-09-04Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in RemissionClinicalTrials.gov · 2026-09-04Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation.Science (New York, N.Y.) · 2026-09-03Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot StudyClinicalTrials.gov · 2026-09-03High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite TrialClinicalTrials.gov · 2026-09-02Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-09-02The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy AdultsClinicalTrials.gov · 2026-09-02Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-09-02Age and Cannabis Co-Use Are Associated with Differences in Experience and Perceived Benefits of Psilocybin: A Retrospective Study.Journal of psychoactive drugs · 2026-09-02Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives.Human psychopharmacology · 2026-09-01Factors Associated with Intentions to Use Psilocybin for Mental Health in Relation to Psychotherapy, Psychiatric Medications, and Natural/Synthetic Options.Journal of psychoactive drugs · 2026-09-01Single-crystal structure determination of psilocybin after dehydration.Acta crystallographica. Section C, Structural chemistry · 2026-09-01Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges.Pharmacological research · 2026-09-01Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when?Expert review of neurotherapeutics · 2026-09-01Active placebo control interventions in pharmacological trials: a scoping review of the development process and a terminological analysis.Journal of clinical epidemiology · 2026-09-01CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-09-01Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026-09-01Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress.Neuropsychopharmacology reports · 2026-09-01Balancing safety and access in Oregon's psilocybin services.The International journal on drug policy · 2026-09-01Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases.Metabolic engineering · 2026-09-01An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept StudyClinicalTrials.gov · 2026-08-31Differential effects of psilocybin derivatives on fentanyl-induced conditioned place preference in male and female mice.Journal of psychopharmacology (Oxford, England) · 2026-08-30A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin.Journal of psychopharmacology (Oxford, England) · 2026-08-29Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility StudyClinicalTrials.gov · 2026-08-28Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.European journal of drug metabolism and pharmacokinetics · 2026-08-28A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility StudyClinicalTrials.gov · 2026-08-28Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session.Psychopharmacology · 2026-08-27